Premix insulin is the way forward for patients treating type 2 diabetes and controlling glucose levels
Press Release Content
Novo Nordisk, a leading healthcare company and a world leader in diabetes care, is continuing to develop new strategies that aim to change the pattern of diabetes treatment management. This is done through a multi-pronged approach involving healthcare professional training, awareness campaigns, patient education and training of other medical personnel involved in the diabetes management.
This year at the Premix Summit on the 24th of November, Novo Nordisk would like to highlight the importance of insulin treatment in relation to management of diabetes. Premix insulin is an extremely effective way to be able to control patients' sugar levels after eating a meal. This summit will bring together diabetes specialists from across Asia and Europe to focus on premix insulin initiation and intensification for optimal patient care, and to discuss the latest insights about the treatment of type 2 diabetes and use of premix insulin.
In addition, the Premix Summit will highlight the epidemics of global obesity and type 2 diabetes as well as the latest clinical data; examine the importance of postprandial glucose (PPG) control in the treatment of diabetes; and discuss the value of and barriers to early insulin initiation as well as intensification.
There are new guidelines on diabetes treatment that will be released at this year's IDF congress to be held in Dubai next month. These guidelines are produced in order to help doctors manage diabetes in all its stages. The new guidelines will give recommendations on how to treat diabetes step-by-step.
Mads Bo Larsen, vice president, Africa, Gulf and India, Novo Nordisk, said: "There is a clear need to further educate the general public about the human, social and economic drama of diabetes and its complications. We believe that awareness combined with prevention, early detection, better disease management and education can make a significant difference, both in terms of people living longer and healthier lives and to maintain a strong workforce."
Tomorrow at the Premix Summit organised by Novo Nordisk, approximately 430 diabetes specialists and doctors from more than 18 countries will gather together to discuss and review treatment guidelines and the diabetes pandemic, both regionally and a on a global scale. They will hear case studies and best practice presentations by specialists from both Europe and Asia.
Notes and contacts
About Novo Nordisk
Novo Nordisk is a healthcare company and a world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs approximately 30,100 employees in 81 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen. Its ADRs are listed on the New York Stock Exchange under the symbol ‘NVO'. For more information, visit www.novonordisk.com.
LATEST PRESS RELEASES
DoubleTree by Hilton announces first resort development in UAE
Posted on Sunday, 15 January 2012Hospitality: read more »
Mulk Holdings Alubond signs new J,V in Turkey
Posted on Sunday, 15 January 2012Construction: read more »
Gate2play launches 1st online payment aggregation system in Middle East
Posted on Saturday, 14 January 2012IT: read more »
Family Forum International presents “Family Office Investment Strategy” – a new way of forums for family business owners
Posted on Friday, 13 January 2012Other: read more »
Celebrate the Chinese year of the Dragon at Eton Institute’s free cultural evening
Posted on Friday, 13 January 2012Education Services: read more »